McDermott David F
Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):716s-720s. doi: 10.1158/1078-0432.CCR-06-1872.
High-dose bolus interleukin 2 (IL-2) was granted Food and Drug Administration approval based on its ability to produce durable complete responses in a small number of patients with metastatic renal cell carcinoma. Results from randomized phase 3 trials suggest that regimens involving lower doses of IL-2, either alone or in combination with IFN, produce fewer tumor regressions of less overall quality. Given the toxicity, expense, and limited efficacy of this treatment, recent studies have focused on identifying predictors of response (or resistance) to IL-2 therapy. This year, investigators launched a clinical trial designed to prospectively determine if patients who are more likely to respond to high-dose IL-2 can be identified before starting therapy. As the list of effective therapies for metastatic renal cell carcinoma grows, improvements in patient selection will be necessary to ensure that patients who might attain a durable remission with IL-2 will not miss this opportunity.
大剂量推注白细胞介素2（IL-2）因其能够使少数转移性肾细胞癌患者产生持久的完全缓解而获得美国食品药品监督管理局的批准。3期随机试验结果表明，低剂量IL-2方案，无论是单独使用还是与干扰素联合使用，产生的肿瘤消退较少，总体质量较低。鉴于这种治疗的毒性、费用和有限的疗效，最近的研究集中在确定对IL-2治疗有反应（或耐药）的预测因素。今年，研究人员开展了一项临床试验，旨在前瞻性地确定在开始治疗前是否能够识别出更有可能对大剂量IL-2产生反应的患者。随着转移性肾细胞癌有效治疗方法的不断增加，有必要改进患者选择，以确保那些可能通过IL-2获得持久缓解的患者不会错过这个机会。
